Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience

Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Vrankar Martina, Stanic Karmen, Jelercic Stasa, Ciric Eva, Vodusek Ana Lina, But-Hadzic Jasna
Format:	article
Langue:	EN
Publié:	Sciendo 2021
Sujets:	non-small cell lung cancer stage iii chemoradiotherapy durvalumab Medical physics. Medical radiology. Nuclear medicine R895-920
Accès en ligne:	https://doaj.org/article/ae2e857754654969af9f34a239d8657f
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:ae2e857754654969af9f34a239d8657f
record_format	dspace
spelling	oai:doaj.org-article:ae2e857754654969af9f34a239d8657f2021-12-05T14:11:10ZClinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience1581-320710.2478/raon-2021-0044https://doaj.org/article/ae2e857754654969af9f34a239d8657f2021-11-01T00:00:00Zhttps://doi.org/10.2478/raon-2021-0044https://doaj.org/toc/1581-3207Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the usage of gemcitabine.Vrankar MartinaStanic KarmenJelercic StasaCiric EvaVodusek Ana LinaBut-Hadzic JasnaSciendoarticlenon-small cell lung cancerstage iiichemoradiotherapydurvalumabMedical physics. Medical radiology. Nuclear medicineR895-920ENRadiology and Oncology, Vol 55, Iss 4, Pp 482-490 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	non-small cell lung cancer stage iii chemoradiotherapy durvalumab Medical physics. Medical radiology. Nuclear medicine R895-920
spellingShingle	non-small cell lung cancer stage iii chemoradiotherapy durvalumab Medical physics. Medical radiology. Nuclear medicine R895-920 Vrankar Martina Stanic Karmen Jelercic Stasa Ciric Eva Vodusek Ana Lina But-Hadzic Jasna Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
description	Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the usage of gemcitabine.
format	article
author	Vrankar Martina Stanic Karmen Jelercic Stasa Ciric Eva Vodusek Ana Lina But-Hadzic Jasna
author_facet	Vrankar Martina Stanic Karmen Jelercic Stasa Ciric Eva Vodusek Ana Lina But-Hadzic Jasna
author_sort	Vrankar Martina
title	Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
title_short	Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
title_full	Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
title_fullStr	Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
title_full_unstemmed	Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
title_sort	clinical outcomes in stage iii non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience
publisher	Sciendo
publishDate	2021
url	https://doaj.org/article/ae2e857754654969af9f34a239d8657f
work_keys_str_mv	AT vrankarmartina clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT stanickarmen clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT jelercicstasa clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT ciriceva clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT vodusekanalina clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience AT buthadzicjasna clinicaloutcomesinstageiiinonsmallcelllungcancerpatientstreatedwithdurvalumabaftersequentialorconcurrentplatinumbasedchemoradiotherapysingleinstituteexperience
_version_	1718371315690242048

Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience

Documents similaires